<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01461993</url>
  </required_header>
  <id_info>
    <org_study_id>B1971011</org_study_id>
    <secondary_id>6108A1-2007</secondary_id>
    <nct_id>NCT01461993</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17</brief_title>
  <official_title>A Phase 2, Randomized, Active-controlled, Observer-blinded Trial, To Assess The Safety, Tolerability, And Immunogenicity Of Gardasil (Registered) (Hpv) Vaccine And Bivalent Rlp2086 Vaccine When Administered Concomitantly In Healthy Subjects Aged &gt;=11 To &lt;18 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical study to assess the safety, tolerance and immunogenic response to Gardasil
      (human papilloma virus (HPV)) and rLP2086 vaccine. Healthy male and female subjects will be
      randomized into 1 of 3 groups; the trial will be an observer-blinded study to the injection
      being given; and, vaccinated with either Gardasil and rLP2086 concomitantly, rLP2086 and
      saline concomitantly, or Gardasil and saline concomitantly. The subjects are adolescent
      children between the ages of 11 and 17 years old.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) of Human Papillomavirus (HPV) Antigens</measure>
    <time_frame>1 month after Vaccination 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Bactericidal Assay Using Human Complement (hSBA) GMTs of PMB80 [A22] and PMB2948 [B24]</measure>
    <time_frame>1 month after Vaccination 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least One Adverse Event (AE)</measure>
    <time_frame>Vaccination 1 up to 1 month after Vaccination 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Seroconversion for Human Papillomavirus (HPV)</measure>
    <time_frame>1 month after Vaccination 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Baseline Seropositive Participants: Group 1 and 3 Participants</measure>
    <time_frame>Before vaccination 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ)</measure>
    <time_frame>Before vaccination 1, 1 month after vaccination (Vac) 2, 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer &gt;= Prespecified Titer Level</measure>
    <time_frame>Before Vaccination 1, 1 month after Vaccination 2, 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titer (GMT)</measure>
    <time_frame>Before Vaccination 1, 1 month after Vaccination 2, 3</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2499</enrollment>
  <condition>Vaccines</condition>
  <condition>Meningococcal Vaccines</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rLP2086 + Gardasil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>rLP2086 and saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Saline + Gardasil</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rLP2086 and Gardasil</intervention_name>
    <description>Gardasil vaccine and rLP2086 injection will be given to the subject concomitantly in Group 1 at Months 0, 2 and 6.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rLP2086</intervention_name>
    <description>Injections of rLP2086 and saline will be given to the subject concomitantly in Group 2 at Months 0, 2 and 6.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gardasil</intervention_name>
    <description>Injections of saline and Gardasil vaccine will be given to the subject concomitantly in Group 3 at Months 0, 2 and 6.</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects from 11 to 17 years old at the time of they start the study.

          -  Subject must be healthy which will be determined by obtaining subject's medical
             history, receiving a physical examination and by judgment of the investigator.

        Exclusion Criteria:

          -  Previous vaccination with any meningococcal serogroup B vaccine.

          -  Previous vaccination with any HPV vaccine.

          -  Contraindication to vaccination with Gardasil or any HPV vaccine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coastal Clinical Research Inc.</name>
      <address>
        <city>Daphne</city>
        <state>Alabama</state>
        <zip>36526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Clinic of Jonesboro, PA</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Pediatric Clinic</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Coast Clinical Trials, LLC</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Care Medical Group</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Health Care</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Health Care</name>
      <address>
        <city>Moreno Valley</city>
        <state>California</state>
        <zip>92557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayview Research Group, LLC</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Trials, LLC</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Research Foundation</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayview Research Group, LLC</name>
      <address>
        <city>Valley Village</city>
        <state>California</state>
        <zip>91607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of the Rockies</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Springs Family Practice</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatrics and Adolescent Medicine, PA</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Atlanta</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatrics and Adolescent Medicine</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northpoint Pediatrics, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Pediatric/Adult Research</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates, Inc.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brownsboro Park Pediatrics</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluegrass Clinical Research, Inc.</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aspen Medical Group/ Odyssey Research</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aspen Medical Group</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allina Health Bandana Square Clinic</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research, PC</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sundance Clinical Research, LLC</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sundance Clinical Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Health Research Institute</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research, Inc.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Child Health Care Associates</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cary Pediatric Center</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center - Duke Health Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durham Pediatrics</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Health Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Internal Medicine Consultants, Inc</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovis Health, LLC dba Essentia Health South University Clinic</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center (CCHMC)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center (CCHMC)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senders Pediatrics</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research, Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of Norman (LION)</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma State University - Center for Health Sciences - Pediatric Research Houston Center</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preferred Primary Care Physicians, Inc.</name>
      <address>
        <city>Carnegie</city>
        <state>Pennsylvania</state>
        <zip>15106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liberty Family Practice</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennridge Pediatric Associates</name>
      <address>
        <city>Sellersville</city>
        <state>Pennsylvania</state>
        <zip>18960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richard K. Ohnmacht, MD</name>
      <address>
        <city>Cranston</city>
        <state>Rhode Island</state>
        <zip>02920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Pediatrics</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charleston</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates, Inc.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Office of Dr. Roberta Braun, MD</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advances In Health, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Healthcare of Northwest Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Center for Drug Development, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch Pediatric Specialty Center</name>
      <address>
        <city>League City</city>
        <state>Texas</state>
        <zip>77573</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Of Texas, Inc</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Steps Pediatrics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Healthcare of Northwest Houston, PA</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Healthcare of Northwest Houston</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Murray Pediatrics</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Associates of Charlottesville</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Office - Pediatric Associates of Charlottesville</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Office - Pediatric Associates of Charlottesville</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Pediatrics</name>
      <address>
        <city>Vienna</city>
        <state>Virginia</state>
        <zip>22180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vancouver Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vancouver Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98686</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monroe Clinic</name>
      <address>
        <city>Monroe</city>
        <state>Wisconsin</state>
        <zip>53566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1971011&amp;StudyName=A%20Clinical%20Trial%20to%20Study%20the%20Safety%2C%20Tolerance%20and%20Immunogenic%20Response%20to%20Gardasil%20and%20Bivalent%20rLP2086%20Vaccine%20When%20Given%20at%20the</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2011</study_first_submitted>
  <study_first_submitted_qc>October 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2011</study_first_posted>
  <results_first_submitted>November 21, 2014</results_first_submitted>
  <results_first_submitted_qc>November 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 26, 2014</results_first_posted>
  <disposition_first_submitted>July 25, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>July 25, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 30, 2014</disposition_first_posted>
  <last_update_submitted>November 21, 2014</last_update_submitted>
  <last_update_submitted_qc>November 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>rLP2086</keyword>
  <keyword>Gardasil</keyword>
  <keyword>HPV</keyword>
  <keyword>meningitis B</keyword>
  <keyword>N. meningitidis serogroup B</keyword>
  <keyword>adolescents</keyword>
  <keyword>single-blind</keyword>
  <keyword>Meningococcal Vaccines</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: rLP2086 + Gardasil</title>
          <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
        </group>
        <group group_id="P2">
          <title>Group 2: rLP2086 + Saline</title>
          <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
        </group>
        <group group_id="P3">
          <title>Group 3: Saline + Gardasil</title>
          <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="999"/>
                <participants group_id="P2" count="998"/>
                <participants group_id="P3" count="502"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="848"/>
                <participants group_id="P2" count="841"/>
                <participants group_id="P3" count="438"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="157"/>
                <participants group_id="P3" count="64"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer met eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet entrance criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: rLP2086 + Gardasil</title>
          <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
        </group>
        <group group_id="B2">
          <title>Group 2: rLP2086 + Saline</title>
          <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
        </group>
        <group group_id="B3">
          <title>Group 3: Saline + Gardasil</title>
          <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="999"/>
            <count group_id="B2" value="998"/>
            <count group_id="B3" value="502"/>
            <count group_id="B4" value="2499"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>11 - less than (&lt;) 15 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="647"/>
                    <measurement group_id="B2" value="660"/>
                    <measurement group_id="B3" value="343"/>
                    <measurement group_id="B4" value="1650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 - &lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="352"/>
                    <measurement group_id="B2" value="338"/>
                    <measurement group_id="B3" value="159"/>
                    <measurement group_id="B4" value="849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="341"/>
                    <measurement group_id="B2" value="332"/>
                    <measurement group_id="B3" value="170"/>
                    <measurement group_id="B4" value="843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="658"/>
                    <measurement group_id="B2" value="666"/>
                    <measurement group_id="B3" value="332"/>
                    <measurement group_id="B4" value="1656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) of Human Papillomavirus (HPV) Antigens</title>
        <time_frame>1 month after Vaccination 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: rLP2086 + Gardasil</title>
            <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>Group 3: Saline + Gardasil</title>
            <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of Human Papillomavirus (HPV) Antigens</title>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="813"/>
                <count group_id="O2" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="451.8" lower_limit="417.50" upper_limit="489.01"/>
                    <measurement group_id="O2" value="550.3" lower_limit="490.44" upper_limit="617.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="892.9" lower_limit="839.52" upper_limit="949.57"/>
                    <measurement group_id="O2" value="1084.3" lower_limit="997.28" upper_limit="1178.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3695.4" lower_limit="3426.32" upper_limit="3985.67"/>
                    <measurement group_id="O2" value="4763.4" lower_limit="4285.85" upper_limit="5294.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="744.0" lower_limit="687.67" upper_limit="804.96"/>
                    <measurement group_id="O2" value="1047.4" lower_limit="939.00" upper_limit="1168.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HPV-6</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 1.5-fold.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HPV-11</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 1.5-fold.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HPV-16</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 1.5-fold.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HPV-18</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 1.5-fold.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Bactericidal Assay Using Human Complement (hSBA) GMTs of PMB80 [A22] and PMB2948 [B24]</title>
        <time_frame>1 month after Vaccination 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: rLP2086 + Gardasil</title>
            <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>Group 2: rLP2086 + Saline</title>
            <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Bactericidal Assay Using Human Complement (hSBA) GMTs of PMB80 [A22] and PMB2948 [B24]</title>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="814"/>
                <count group_id="O2" value="812"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB80 [A22] (N= 803, 801)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" lower_limit="50.22" upper_limit="56.66"/>
                    <measurement group_id="O2" value="57.8" lower_limit="54.44" upper_limit="61.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948 [B24] (N= 788, 793)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8" lower_limit="24.14" upper_limit="27.56"/>
                    <measurement group_id="O2" value="28.0" lower_limit="26.24" upper_limit="29.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PMB80 [A22]</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 1.5-fold.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PMB2948 [B24]</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 1.5-fold.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Seroconversion for Human Papillomavirus (HPV)</title>
        <time_frame>1 month after Vaccination 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: rLP2086 + Gardasil</title>
            <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>Group 3: Saline + Gardasil</title>
            <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Seroconversion for Human Papillomavirus (HPV)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="809"/>
                <count group_id="O2" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-6 (N= 802, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4"/>
                    <measurement group_id="O2" value="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-11 (N= 801, 417)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6"/>
                    <measurement group_id="O2" value="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 (N= 800, 413)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6"/>
                    <measurement group_id="O2" value="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 (N= 805, 418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5"/>
                    <measurement group_id="O2" value="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Baseline Seropositive Participants: Group 1 and 3 Participants</title>
        <time_frame>Before vaccination 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: rLP2086 + Gardasil</title>
            <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>Group 3: Saline + Gardasil</title>
            <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Baseline Seropositive Participants: Group 1 and 3 Participants</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="814"/>
                <count group_id="O2" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ)</title>
        <time_frame>Before vaccination 1, 1 month after vaccination (Vac) 2, 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: rLP2086 + Gardasil</title>
            <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>Group 2: rLP2086 + Saline</title>
            <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="814"/>
                <count group_id="O2" value="812"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Vaccination 1:PMB80[A22] 1:16 (N= 794, 799)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7"/>
                    <measurement group_id="O2" value="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB80[A22] 1:16 (N= 794, 801)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.0"/>
                    <measurement group_id="O2" value="85.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB80[A22] 1:16 (N= 803, 801)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.0"/>
                    <measurement group_id="O2" value="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1:PMB2001[A56] 1:8(N= 757, 740)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2001[A56] 1:8 (N= 790,795)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5"/>
                    <measurement group_id="O2" value="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2001[A56] 1:8 (N= 796,802)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9"/>
                    <measurement group_id="O2" value="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1:PMB2948[B24] 1:8(N= 801, 793)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2948[B24] 1:8 (N= 770,770)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.6"/>
                    <measurement group_id="O2" value="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2948[B24] 1:8 (N= 788,793)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5"/>
                    <measurement group_id="O2" value="92.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1:PMB2707[B44] 1:8(N= 806, 805)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2707[B44] 1:8 (N= 783,776)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5"/>
                    <measurement group_id="O2" value="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2707[B44] 1:8 (N= 799,795)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.7"/>
                    <measurement group_id="O2" value="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer &gt;= Prespecified Titer Level</title>
        <time_frame>Before Vaccination 1, 1 month after Vaccination 2, 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: rLP2086 + Gardasil</title>
            <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>Group 2: rLP2086 + Saline</title>
            <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer &gt;= Prespecified Titer Level</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="814"/>
                <count group_id="O2" value="812"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Vaccination 1: PMB80 [A22] 1:4 (N=794,799)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2"/>
                    <measurement group_id="O2" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB80 [A22] 1:8 (N=794,799)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2"/>
                    <measurement group_id="O2" value="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB80 [A22] 1:32 (N=794,799)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4"/>
                    <measurement group_id="O2" value="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB80 [A22] 1:64 (N=794,799)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB80[A22] 1:128 (N=794,799)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB80 [A22] 1:4 (N=794,801)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.8"/>
                    <measurement group_id="O2" value="86.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB80 [A22] 1:8 (N=794,801)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.2"/>
                    <measurement group_id="O2" value="86.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB80 [A22] 1:32 (N=794,801)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.9"/>
                    <measurement group_id="O2" value="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB80 [A22] 1:64 (N=794,801)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9"/>
                    <measurement group_id="O2" value="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB80 [A22] 1:128 (N=794,801)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0"/>
                    <measurement group_id="O2" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB80 [A22] 1:4 (N=803,801)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3"/>
                    <measurement group_id="O2" value="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB80 [A22] 1:8 (N=803,801)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3"/>
                    <measurement group_id="O2" value="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB80 [A22] 1:32 (N=803,801)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.3"/>
                    <measurement group_id="O2" value="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB80 [A22] 1:64 (N=803,801)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.0"/>
                    <measurement group_id="O2" value="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB80 [A22] 1:128 (N=803,801)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1"/>
                    <measurement group_id="O2" value="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2001[A56] 1:4 (N=757,740)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4"/>
                    <measurement group_id="O2" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2001[A56] 1:16(N=757,740)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0"/>
                    <measurement group_id="O2" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2001[A56] 1:32(N=757,740)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1"/>
                    <measurement group_id="O2" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2001[A56] 1:64(N=757,740)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1:PMB2001[A56] 1:128(N=757,740)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2001 [A56] 1:4 (N=790,795)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8"/>
                    <measurement group_id="O2" value="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2001[A56] 1:16 (N=790,795)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2"/>
                    <measurement group_id="O2" value="98.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2001[A56] 1:32 (N=790,795)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3"/>
                    <measurement group_id="O2" value="93.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2001[A56] 1:64 (N=790,795)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.6"/>
                    <measurement group_id="O2" value="76.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2001[A56] 1:128(N=790,795)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4"/>
                    <measurement group_id="O2" value="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2001 [A56] 1:4 (n=796,802)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.1"/>
                    <measurement group_id="O2" value="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2001[A56] 1:16 (N=796,802)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9"/>
                    <measurement group_id="O2" value="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2001[A56] 1:32 (N=796,802)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7"/>
                    <measurement group_id="O2" value="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2001[A56] 1:64 (N=796,802)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1"/>
                    <measurement group_id="O2" value="89.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2001[A56] 1:128(N=796,802)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6"/>
                    <measurement group_id="O2" value="67.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2948[B24] 1:4 (N=801,793)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                    <measurement group_id="O2" value="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2948[B24] 1:16(N=801,793)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2948[B24] 1:32(N=801,793)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2948[B24] 1:64(N=801,793)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1:PMB2948[B24] 1:128(N=801,793)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2948 [B24] 1:4 (N=770,770)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.9"/>
                    <measurement group_id="O2" value="77.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2948[B24] 1:16 (N=770,770)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.2"/>
                    <measurement group_id="O2" value="68.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2948[B24] 1:32 (N=770,770)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9"/>
                    <measurement group_id="O2" value="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2948[B24] 1:64 (N=770,770)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1"/>
                    <measurement group_id="O2" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2948[B24] 1:128(N=770,770)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2948 [B24] 1:4 (N=788,793)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.1"/>
                    <measurement group_id="O2" value="92.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2948[B24] 1:16 (N=788,793)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.3"/>
                    <measurement group_id="O2" value="89.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2948[B24] 1:32 (N=788,793)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.2"/>
                    <measurement group_id="O2" value="60.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2948[B24] 1:64 (N=788,793)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9"/>
                    <measurement group_id="O2" value="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2948[B24] 1:128(N=788,793)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6"/>
                    <measurement group_id="O2" value="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2707[B44] 1:4 (N=806,805)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2707[B44] 1:16(N=806,805)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2707[B44] 1:32(N=806,805)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2707[B44] 1:64(N=806,805)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1:PMB2707[B44] 1:128(N=806,805)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2707 [B44] 1:4 (N=783,776)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7"/>
                    <measurement group_id="O2" value="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2707[B44] 1:16 (N=783,776)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4"/>
                    <measurement group_id="O2" value="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2707[B44] 1:32 (N=783,776)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7"/>
                    <measurement group_id="O2" value="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2707[B44] 1:64 (N=783,776)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2"/>
                    <measurement group_id="O2" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2707[B44] 1:128(N=783,776)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2707 [B44] 1:4 (N=799,795)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.4"/>
                    <measurement group_id="O2" value="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2707[B44] 1:16 (N=799,795)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0"/>
                    <measurement group_id="O2" value="82.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2707[B44] 1:32 (N=799,795)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7"/>
                    <measurement group_id="O2" value="62.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2707[B44] 1:64 (N=799,795)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7"/>
                    <measurement group_id="O2" value="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2707[B44] 1:128(N=799,795)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1"/>
                    <measurement group_id="O2" value="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titer (GMT)</title>
        <time_frame>Before Vaccination 1, 1 month after Vaccination 2, 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: rLP2086 + Gardasil</title>
            <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>Group 2: rLP2086 + Saline</title>
            <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titer (GMT)</title>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="814"/>
                <count group_id="O2" value="812"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Vaccination 1: PMB80 [A22] (N=794,799)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" lower_limit="9.28" upper_limit="9.96"/>
                    <measurement group_id="O2" value="9.9" lower_limit="9.58" upper_limit="10.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB80 [A22] (N=794,801)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9" lower_limit="29.96" upper_limit="33.94"/>
                    <measurement group_id="O2" value="33.7" lower_limit="31.69" upper_limit="35.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2001 [A56] (N=757,740)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="4.78" upper_limit="5.32"/>
                    <measurement group_id="O2" value="5.0" lower_limit="4.75" upper_limit="5.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2001 [A56] (N=790,795)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.6" lower_limit="66.17" upper_limit="75.34"/>
                    <measurement group_id="O2" value="76.3" lower_limit="71.93" upper_limit="80.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2001 [A56] (N=796,802)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.2" lower_limit="110.14" upper_limit="124.76"/>
                    <measurement group_id="O2" value="128.2" lower_limit="120.65" upper_limit="136.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2948 [B24] (N=801,793)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="4.23" upper_limit="4.46"/>
                    <measurement group_id="O2" value="4.5" lower_limit="4.35" upper_limit="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2948 [B24] (N=770,770)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="13.88" upper_limit="16.15"/>
                    <measurement group_id="O2" value="16.3" lower_limit="15.15" upper_limit="17.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2707 [B44] (N=806,805)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="4.04" upper_limit="4.15"/>
                    <measurement group_id="O2" value="4.2" lower_limit="4.10" upper_limit="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2707 [B44] (N=783,776)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="10.21" upper_limit="12.01"/>
                    <measurement group_id="O2" value="11.9" lower_limit="10.94" upper_limit="12.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2707 [B44] (N=799,795)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" lower_limit="24.99" upper_limit="29.68"/>
                    <measurement group_id="O2" value="31.9" lower_limit="29.25" upper_limit="34.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least One Adverse Event (AE)</title>
        <time_frame>Vaccination 1 up to 1 month after Vaccination 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: rLP2086 + Gardasil</title>
            <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O2">
            <title>Group 2: rLP2086 + Saline</title>
            <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Saline + Gardasil</title>
            <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One Adverse Event (AE)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="992"/>
                <count group_id="O2" value="990"/>
                <count group_id="O3" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9" lower_limit="40.7" upper_limit="47.0"/>
                    <measurement group_id="O2" value="41.7" lower_limit="38.6" upper_limit="44.9"/>
                    <measurement group_id="O3" value="49.5" lower_limit="45.0" upper_limit="54.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE reported from Vaccination 1 to 1 month after last administration of investigational product (bivalent rLP2086/saline/Gardasil). SAE reported from Vaccination 1 to 6 months after last of investigational product (bivalent rLP2086/saline/Gardasil)</time_frame>
      <desc>Events collected on case report form were reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1: rLP2086 + Gardasil</title>
          <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
        </group>
        <group group_id="E2">
          <title>Group 2: rLP2086 + Saline</title>
          <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
        </group>
        <group group_id="E3">
          <title>Group 3: Saline + Gardasil</title>
          <description>Randomized to receive on a 0, 2-, 6- month schedule</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphoid tissue hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burns first degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Epiphysiolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Nodular fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Cyclothymic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Oppositional defiant disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="308" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="289" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="168" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="990"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

